Cancer Monoclonal Antibodies Market

SKU: DMPH222 | Last Updated On: Feb 01 2023 | Available Formats

>Cancer Monoclonal Antibodies Market Expected to reach at a high CAGR of 9.50% By 2023- 2030:

Cancer Monoclonal Antibodies Market is segmented by Monoclonal Antibodies (Humanized, Murine, Chimeric, Human, Rat, Immunotoxin, Immunoadhesin, and Others), By Monoclonal Antibody Therapies (Bevacizumab, Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), and Other), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, and Other Applications), and Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2023- 2030.

Cancer Monoclonal Antibodies Market size was valued at USD 46,474.80 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 9.50% over the forecast period 2023- 2030. Monoclonal antibodies are used to treat cancer in a variety of ways. They're a sort of targeted cancer therapy, meaning they're made to interact with certain targets.

Cancer Monoclonal Antibodies Market Scope:

Metrics

Details

Market CAGR

9.50%

Segments Covered

By Monoclonal Antibodies, By Monoclonal Antibodies Therapies, By Application, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Know more insights into the Market, Get Our Sample Brochure

Market Dynamics

The factors influencing the global cancer monoclonal antibodies market are the growing demand for cancer treatment and the increasing prevalence of cancer.

The growing demand for cancer treatment is expected to drive the market growth in the forecast period

Monoclonal antibodies are used to treat cancer in a variety of ways. They're a sort of targeted cancer therapy, meaning they're made to interact with certain targets. To learn more about targeted therapy, click here. Some monoclonal antibodies are also used in cancer immunotherapy as they help turn the immune system against cancer.

Some monoclonal antibodies label cancer cells so the immune system can recognize and eliminate them more effectively. Rituximab, for instance, attaches to a protein on B cells and some types of cancer cells called CD20, allowing the immune system to kill them. White blood cells, known as B cells, are a type of white blood cell. Other monoclonal antibodies help immune cells attack cancer cells by bringing T cells close to them. Blincyto binds to CD19, a protein located on the surface of leukemia cells, and CD3, a protein found on the surface of T cells. This procedure allows T lymphocytes to approach the leukemia cells near enough to respond to and kill them.

Combinations of tumor-targeted mAbs and ICB have shown various promising paths for increasing mAb therapy's clinical impact. Furthermore, mutations in the antibody target, as well as any associated signaling pathways, are key biomarkers for mAb efficacy and resistance. To overcome resistance, future mAb therapy regimens must include inhibitors of these alternate signaling pathways. Monoclonal antibody-based treatment paradigms will continue to evolve, potentially providing curative therapy for many cancer patients

Side effects associated with monoclonal antibodies are expected to hamper the market growth

Monoclonal antibodies can have various adverse effects that vary from person to person. Monoclonal antibodies, like most types of immunotherapy, can produce skin responses at the needle site and flu-like symptoms. Some of the needle site reactions are pain, swelling, soreness, redness, itchiness, and rash.

Monoclonal antibodies can also create problems such as sores in the mouth and on the skin that can develop into serious illnesses, blood pressure that is too high, heart failure due to congestive heart failure, coronary artery disease, and inflammatory bronchitis. While taking monoclonal antibodies, one may experience mild to severe adverse responses. The reaction is severe enough to cause death in rare situations.

Monoclonal antibodies can also cause capillary leak syndrome. This illness results in dangerously low blood pressure as fluid and proteins leak out of small blood capillaries and spread into surrounding tissues. Multiple organ failure and shock are possible outcomes of capillary leak syndrome.

Industry Analysis

The global cancer monoclonal antibodies market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement scenario, pipeline analysis, pricing analysis, etc.

COVID-19 Impact Analysis

Monoclonal antibodies are used to treat a variety of diseases, including cancer. They're also used to treat disorders including Crohn's disease and rheumatoid arthritis, as well as graft-versus-host disease. Monoclonal antibodies are now being utilized to treat coronavirus infections (COVID-19). While the FDA has granted emergency use authorization for these COVID-19-targeted medications.

According to a study presented at the NCCN 2022 Annual Conference, monoclonal antibody (mAb) infusions can minimize the incidence of COVID-19-related hospitalization in cancer patients. Hence, the increasing demand for monoclonal antibodies during covid-19 is expected to drive cancer monoclonal antibodies market growth.

Segment Analysis

Bevacizumab (Avastin) segment is expected to dominate the market growth

Avastin is the commercial name for the anti-cancer medicine bevacizumab, which belongs to the monoclonal antibody class of medications. A molecule produced by the body in reaction to a foreign invader or antigen is known as an antibody. A monoclonal antibody is a type of antibody made in the lab to target and block specific proteins.

These medications are targeted therapies because they are particularly selective for the molecules against which they were developed. Bevacizumab (Avastin) is a humanized monoclonal IgG1 antibody that has been recombinantly produced.

Monoclonal antibodies bind to certain proteins (receptors) on the surface of cancer cells and recognize them. When a monoclonal antibody binds to the target receptor, it activates the immune system, attacking the cancer cells and causing them to self-destruct. The antibody can also stop the receptor from stimulating tumor growth, proliferation, or angiogenesis by binding to another protein (blood vessel formation).

Bevacizumab has been approved by the US Food and Drug Administration for the first-line treatment of patients with advanced or metastatic (cancer that has spread to important organs) colon or rectum carcinoma. The treatment can benefit from advanced non-small cell lung and advanced cancers of the breast, kidney, and intestine.

Bevacizumab can be administered with chemotherapy or, in the case of kidney cancer, with interferon. Every two or three weeks, the medication is administered as an infusion into a vein. The first and second infusions of bevacizumab are usually given over 90 minutes and 60 minutes, respectively, with subsequent infusions lasting roughly 30 minutes.

Geographical Analysis

The North American region is expected to hold the largest market share in the global cancer monoclonal antibodies market

The increasing prevalence of cancer and growing research and development are expected to drive market growth. In the United States, 1,752,735 new cancer cases were reported in 2019, and 599,589 cancer deaths. 439 new cancer cases were reported for every 100,000 people, with 146 dying from cancer.

Moreover, companies are manufacturing monoclonal antibodies and are expected to boost the market growth in this region, For instance, Amgen Inc., an American multinational biopharmaceutical company, is manufacturing Vectibix (panitumumab):  Vectibix® in combination with FOLFOX chemotherapy is designed for patients with wild-type RAS metastatic colorectal cancer (mCRC), and a RAS test can show what type of mCRC one can have.

Competitive Landscape

The global cancer monoclonal antibodies market is moderately competitive with mergers, acquisitions and product launches. Some of the key players in the market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG and Spectrum Pharmaceuticals Inc., Genentech USA, Inc.

Company Profile Analysis

F. Hoffmann-La Roche Ltd

Overview: Roche, or F. Hoffmann-La Roche AG, is a Swiss global healthcare corporation that operates under two divisions pharmaceuticals and diagnostics. The company has its headquarters in Basel, Switzerland.

Product Portfolio: Atezolizumab is, sold under the brand name Tecentriq, a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, and hepatocellular carcinoma.

The global cancer monoclonal antibodies market report would provide an access to an approx. 45+market data table, 40+figures, and 180 pages.

Frequently Asked Questions

What is the Projected CAGR value of the Cancer Monoclonal Antibodies Market?

Cancer Monoclonal Antibodies Market is expected to grow at a CAGR of 9.5% during the forecasting period 2023- 2030.

Which region controlled the global market during 2023- 2030?

North America region Controls the Cancer Monoclonal Antibodies Market during 2023- 2030.

Which is the fastest growing region in the Cancer Monoclonal Antibodies Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Monoclonal Antibody Therapeutics Market

Chronic Lymphocytic Leukemia Therapeutics Market

Cancer Treatment Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest